Etanercept therapy in patients with autoimmunity and hepatitis C
- 1 December 2003
- journal article
- review article
- Published by Informa UK Limited in Journal of Dermatological Treatment
- Vol. 14 (4), 229-232
- https://doi.org/10.1080/09546630310020470
Abstract
Accumulated data suggest that etanercept may be a therapeutic option in patients with hepatitis C and coexisting autoimmune disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis and ankylosing spondylitis. Additionally, etanercept may actually be of benefit, when used in combination with standard treatments, for hepatitis C.Keywords
This publication has 27 references indexed in Scilit:
- Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probesLupus, 2003
- SERUM TUMOUR NECROSIS FACTOR-α AND TRANSFORMING GROWTH FACTOR-β LEVELS IN CHRONIC HEPATITIS C PATIENTS ARE IMMUNOMODULATED BY THERAPYCytokine, 2002
- Cytokines and autoimmunityNature Reviews Immunology, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Increased peripheral production of TNF-a and mucosal levels of activated NFkB predict relapse after treatment with infliximab in patients with Crohn's diseaseGastroenterology, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- EtanerceptDrugs, 1999
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987